NVS - Novartis AG
94.92 0.00 (0.00%)
After hours: 4:17PM EST
| Previous close | 95.21 |
| Open | 95.09 |
| Bid | 94.87 x 800 |
| Ask | 94.75 x 800 |
| Day's range | 94.45 - 95.17 |
| 52-week range | 74.97 - 96.06 |
| Volume | 2,118,703 |
| Avg. volume | 1,550,406 |
| Market cap | 214.693B |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | 18.73 |
| EPS (TTM) | 5.07 |
| Earnings date | N/A |
| Forward dividend & yield | 2.83 (2.98%) |
| Ex-dividend date | 02-Mar-2019 |
| 1y target est | 101.00 |
- Zacks
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
- Zacks
Roche's Risdiplam Meets Primary Endpoint in Infants Study
Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.
- Zacks
Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe
Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.
- Zacks
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.
- Zacks
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
- Zacks
Is Novartis AG (NVS) A Suitable Pick for Value Investors?
Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.
- Zacks
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
- Zacks
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
- Financial Times
Gene therapies test Europe’s willingness to pay
The drive to cure deadly diseases is about to enter a new and demanding phase as the pharmaceutical industry prepares for the first time to test the appetite for hyper-expensive gene therapies in Europe. The willingness of traditionally cash-strapped European health systems to pay for these innovative treatments will affect future investment in the field. , a treatment for rare blood disorder Beta thalassaemia that is manufactured by Bluebird Bio.
- Reuters
Roche aims to 'underwhelm' on SMA drug price to challenge rivals
ZURICH/SAN FRANCISCO (Reuters) - Swiss drugmaker Roche plans to price its oral spinal muscular atrophy drug (SMA) risdiplam aggressively to challenge two of the world's most expensive medicines, Biogen's Spinraza and Novartis's gene therapy Zolgensma. Spinraza's list price is $750,000 in the first year, and $375,000 thereafter, while Novartis's gene therapy for the genetic muscle wasting disease lists at $2.1 million, making it the drug industry's most expensive one-time treatment. While Roche has not released risdiplam's price, drug chief Bill Anderson said the Basel-based company will price the drug much as it did its haemophilia A medicine Hemlibra in 2017, when it undercut traditional therapies made by rivals NovoNordisk and Takeda to help win patients.
- Reuters
Novartis to speed access to $10 billion heart drug via NHS deal
Novartis and Britain's National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country's health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021. Novartis hopes the NHS deal will boost sales of cholesterol-lowering inclisiran, which the Swiss drugmaker bought in a deal announced last year for nearly $10 billion (£7.70 billion) and predicts will be a top seller. Inclisiran was submitted to U.S. regulators last year, and Novartis expects a European submission in coming weeks.
- Zacks
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
- Financial Times
UK’s NHS teams with Novartis to launch heart attack drug trial
Britons at risk of heart attacks are set to receive a twice-yearly injection in a bid to save up to 30,000 lives over a decade, under one of the biggest population-wide prevention initiatives undertaken anywhere in the world. Inclisiran, a cholesterol-lowering medicine, will first be tested in a large UK clinical trial that will make use of the extensive National Health Service data base to identify and track suitable patients. Assuming the trial is successful, the drug will be made available across the English health service.
- Zacks
Regeneron's Phase II Candidate Promising in Primary Analysis
Regeneron (REGN) announces encouraging results from the phase II study on rare bone disease candidate.
- Zacks
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
- Zacks
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
- Reuters
Novartis, Merck and Allergan join those raising U.S. drug prices for 2020
Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the price increases are below 10%, with the median price increase around 5%, according to 3 Axis. Swiss drugmaker Novartis raised prices on nearly 30 drugs including psoriasis treatment Cosentyx and multiple sclerosis medicine Gilenya, 3 Axis said.
- Zacks
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
- Zacks
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
- Zacks
Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta
Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.
- Zacks
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
- GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against Novartis AG – NVS
NEW YORK, Dec. 27, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
- Zacks
Epizyme (EPZM) Shares Soar on Lead Candidate's Progress
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
- Zacks
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
